Cargando…
Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834045/ https://www.ncbi.nlm.nih.gov/pubmed/35162109 http://dx.doi.org/10.3390/ijerph19031085 |
_version_ | 1784649085204037632 |
---|---|
author | Buju, Roger T. Akilimali, Pierre Z. Kamangu, Erick N. Mesia, Gauthier K. Kayembe, Jean Marie N. Situakibanza, Hippolyte N. |
author_facet | Buju, Roger T. Akilimali, Pierre Z. Kamangu, Erick N. Mesia, Gauthier K. Kayembe, Jean Marie N. Situakibanza, Hippolyte N. |
author_sort | Buju, Roger T. |
collection | PubMed |
description | The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing armed conflict since 2017 in the city of Bunia in the DRC. We conducted a cohort study of 468 patients living with HIV under DTG in all health facilities in Bunia. We calculated the proportion of participants with an HIV RNA of below 50 copies per milliliter. About three in four patients (72.8%) in this cohort had a viral load (VL) of <50 copies/mL after 6–12 months. After controlling for the effect of other covariates, the likelihood of having non-suppression remained significantly lower among the 25–34 age group and self-reported naïve patients with a baseline VL of ≥50 copies/mL. The likelihood of having non-suppression remained significantly higher among those who were at advanced stages of the disease, those with abnormal serum creatinine, those with high baseline HIV viremia over 1000 copies/mL, and the Sudanese ethnic group compared to the reference groups. This study suggests that we should better evaluate adherence, especially among adolescents and economically vulnerable populations, such as the Sudanese ethnic group in the city of Bunia. This suggests that an awareness of the potential effects of DTG and tenofovir is important for providers who take care of HIV-positive patients using antiretroviral therapy (ART), especially those with abnormal serum creatinine levels before starting treatment. |
format | Online Article Text |
id | pubmed-8834045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88340452022-02-12 Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study Buju, Roger T. Akilimali, Pierre Z. Kamangu, Erick N. Mesia, Gauthier K. Kayembe, Jean Marie N. Situakibanza, Hippolyte N. Int J Environ Res Public Health Article The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing armed conflict since 2017 in the city of Bunia in the DRC. We conducted a cohort study of 468 patients living with HIV under DTG in all health facilities in Bunia. We calculated the proportion of participants with an HIV RNA of below 50 copies per milliliter. About three in four patients (72.8%) in this cohort had a viral load (VL) of <50 copies/mL after 6–12 months. After controlling for the effect of other covariates, the likelihood of having non-suppression remained significantly lower among the 25–34 age group and self-reported naïve patients with a baseline VL of ≥50 copies/mL. The likelihood of having non-suppression remained significantly higher among those who were at advanced stages of the disease, those with abnormal serum creatinine, those with high baseline HIV viremia over 1000 copies/mL, and the Sudanese ethnic group compared to the reference groups. This study suggests that we should better evaluate adherence, especially among adolescents and economically vulnerable populations, such as the Sudanese ethnic group in the city of Bunia. This suggests that an awareness of the potential effects of DTG and tenofovir is important for providers who take care of HIV-positive patients using antiretroviral therapy (ART), especially those with abnormal serum creatinine levels before starting treatment. MDPI 2022-01-19 /pmc/articles/PMC8834045/ /pubmed/35162109 http://dx.doi.org/10.3390/ijerph19031085 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Buju, Roger T. Akilimali, Pierre Z. Kamangu, Erick N. Mesia, Gauthier K. Kayembe, Jean Marie N. Situakibanza, Hippolyte N. Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study |
title | Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study |
title_full | Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study |
title_fullStr | Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study |
title_full_unstemmed | Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study |
title_short | Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study |
title_sort | predictors of viral non-suppression among patients living with hiv under dolutegravir in bunia, democratic republic of congo: a prospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834045/ https://www.ncbi.nlm.nih.gov/pubmed/35162109 http://dx.doi.org/10.3390/ijerph19031085 |
work_keys_str_mv | AT bujurogert predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy AT akilimalipierrez predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy AT kamanguerickn predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy AT mesiagauthierk predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy AT kayembejeanmarien predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy AT situakibanzahippolyten predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy |